Phase II study of linifanib in KRAS mutated metastatic refractory colorectal cancer

被引：0
|
作者：
Chan, E. [1 ]
Ayers, G. D. [2 ]
Goff, L. [1 ]
McClanahan, P. [3 ]
Holloway, M. [3 ]
Ciombor, K. [1 ]
Smith, S. J. [1 ]
Ancell, K. [1 ]
Cardin, D. B. [1 ]
Berlin, J. [1 ]
机构：
[1] Vanderbilt Univ, Med Ctr, Div Med Oncol, Nashville, TN USA
[2] Vanderbilt Univ, Med Ctr, Ctr Quantitat Sci, Nashville, TN USA
[3] Vanderbilt Univ, Med Ctr, Nashville, TN USA
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2369
引用
收藏
页码：S549 / S549
页数：1
相关论文
共 50 条
  • [1] Phase II study of the Multikinase inhibitor of angiogenesis, Linifanib, in patients with metastatic and refractory colorectal cancer expressing mutated KRAS
    Emily Chan
    Laura W. Goff
    Dana B. Cardin
    Kristin Ancell
    Stephen James Smith
    Jennifer G. Whisenant
    Fei Ye
    Jordan D. Berlin
    Investigational New Drugs, 2017, 35 : 491 - 498
  • [2] Phase II study of the Multikinase inhibitor of angiogenesis, Linifanib, in patients with metastatic and refractory colorectal cancer expressing mutated KRAS
    Chan, Emily
    Goff, Laura W.
    Cardin, Dana B.
    Ancell, Kristin
    Smith, Stephen James
    Whisenant, Jennifer G.
    Ye, Fei
    Berlin, Jordan D.
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (04) : 491 - 498
  • [3] A Phase II Study of Sorafenib Combined With Cetuximab in EGFR-Expressing, KRAS-Mutated Metastatic Colorectal Cancer
    Do, Khanh
    Cao, Liang
    Kang, Zhigang
    Turkbey, Baris
    Lindenberg, Maria L.
    Larkins, Erin
    Holkova, Beata
    Steinberg, Seth M.
    Raffeld, Mark
    Peer, Cody J.
    Figg, William D.
    Eugeni, Michelle
    Jacobs, Paula
    Choyke, Peter
    Wright, John J.
    Doroshow, James H.
    Kummar, Shivaani
    CLINICAL COLORECTAL CANCER, 2015, 14 (03) : 154 - 161
  • [4] Temozolimide and capecitabine in patients with refractory KRAS wildtype metastatic colorectal cancer. A phase II trial
    Qvortrup, C.
    Keldsen, N.
    Andersen, F.
    Jensen, H. A.
    Krogh, M.
    Vestermark, L. W.
    Bjerregaard, J. K.
    Pfeiffer, P.
    ANNALS OF ONCOLOGY, 2016, 27
  • [5] Immunomodulatory Effects in a Phase II Study of Lenalidomide Combined with Cetuximab in Refractory KRAS-Mutant Metastatic Colorectal Cancer Patients
    Gandhi, Anita K.
    Shi, Tao
    Li, Mingyu
    Jungnelius, Ulf
    Romano, Alfredo
    Tabernero, Josep
    Siena, Salvatore
    Schafer, Peter H.
    Chopra, Rajesh
    PLOS ONE, 2013, 8 (11):
  • [6] Microenvironment targets in KRAS-mutated metastatic colorectal cancer
    Marchio, Serena
    Bartolini, Alice
    Cardaci, Sabrina
    Soster, Marco
    Corti, Giorgio
    Lamba, Simona
    Bussolino, Federico
    Cora', Davide
    Nicolantonio, Federica D.
    CANCER RESEARCH, 2014, 74 (19)
  • [7] A phase I/II study of nintedanib and capecitabine for refractory metastatic colorectal cancer
    Boland, Patrick M.
    Ebos, John M. L.
    Attwood, Kristopher
    Mastri, Michalis
    Fountzilas, Christos
    Iyer, Renuka, V
    Banker, Christopher
    Goey, Andrew K. L.
    Bies, Robert
    Ma, Wen Wee
    Fakih, Marwan
    JNCI CANCER SPECTRUM, 2024, 8 (03)
  • [8] A phase II study on third-line chemotherapy combined bevacizumab with S-1 for metastatic colorectal cancer with mutated KRAS: SAVIOR study
    Takagane, Akinori
    Miyake, Yasuhiro
    Kobayashi, Kouji
    Nagata, Naoki
    Sato, Atsushi
    Ogata, Yutaka
    Fukunaga, Mutsumi
    Otsuka, Koki
    Takahashi, Takao
    Matsumoto, Hidetomo
    Negoro, Yuji
    Matsubara, Yoshihiro
    Yoshida, Motoki
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [9] Advanced therapies on BRAF-mutated and KRAS-mutated metastatic colorectal cancer
    LI Zi-nan
    YU Li-feng
    WANG Jia-qi
    NIU Yan-xin
    WANG Xin-yu
    ZHAO Lin
    中国药理学与毒理学杂志, 2019, (10) : 883 - 883
  • [10] Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer
    Kopetz, Scott
    Desai, Jayesh
    Chan, Emily
    Hecht, Joel Randolph
    O'Dwyer, Peter J.
    Maru, Dipen
    Van Morris
    Janku, Filip
    Dasari, Arvind
    Chung, Woonbook
    Issa, Jean-Pierre J.
    Gibbs, Peter
    James, Brian
    Powis, Garth
    Nolop, Keith B.
    Bhattacharya, Suman
    Saltz, Leonard
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (34) : 4032 - 4038
12345